Kura Oncology, INC
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersSan Diego, CA
US patents32
SAM.gov UEIPSETF5F98MV1
CAGE code129S0
Incorporated inDE
LEI5493005QORQTZCZYOP39
Brands
This company sells these brands.
- novel cancer therapeutics
- precision medicines
- menin inhibition
- farnesyl transferase inhibitors
- acute leukemias
- neck cancer
Named on the company’s own website, read JUL 29, 2026
Open positions
Openings read from Kura Oncology, INC’s own job board on Greenhouse, last checked NOV 7, 2026. FactoryRegistry does not host applications — each title opens the posting where the company published it.
- MSL/Sr. MSL - North Central (IL, MI, MN, NE, ND, SD, WI, IA, PA)Field Based: Mid-Atlantic · Medical Affairs · posted NOV 6, 2026
- Senior Manager/Associate Director, Scientific Communications & Publicationsremote · Medical Affairs · posted OCT 21, 2026
- Manager, Biosample OperationsBoston, Mass or Remote · Clinical Operations · posted OCT 13, 2026
- Manager/Sr. Manager, IR & Corporate CommunicationsKura Oncology, INC · San Diego, CA · Corporate · posted OCT 9, 2026
- Senior Director, HR Business PartnerUnited States · Human Resources · posted OCT 9, 2026
- Director, Clinical Business OperationsBoston, MA · Clinical Operations · posted SEP 30, 2026
- Director, Medical & Regulatory WritingRemote · Regulatory Affairs · posted SEP 30, 2026
- Oncology Account Manager - Indianapolis/KY/ILField Based · Commercial · posted SEP 15, 2026
- Assoc Director/Director, ITremote · IT/Facilities · posted SEP 11, 2026
- CTL/Senior Clinical Trial LeaderBoston, MA · Clinical Operations · posted AUG 21, 2025
Supplier designations
For Profit OrganizationManufacturer of Goods
Self-certified by the company in its SAM.gov registration
Patents
32 US patents granted 2017–2025, 16 of them in the five years to SEP 2025.
Pharmaceuticals 24Organic fine chemistry 7
- Crystalline forms of a menin inhibitorUS 12,410,184 · granted SEP 9, 2025
- Macrocyclic compounds and compositions, and methods of preparing and using the sameUS 12,018,011 · granted JUN 25, 2024
- Methods for treating hematological malignancies and Ewing's sarcomaUS 11,944,627 · granted APR 2, 2024
- Thienopyrimidine and thienopyridine compounds and methods of use thereofUS RE49687 · granted OCT 10, 2023
- Substituted inhibitors of menin-MLL and methods of useUS 11,673,898 · granted JUN 13, 2023
Newest 5 shown · Granted to Kura Oncology, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Kura Oncology, INC | San Diego | CA | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.